7.105
price down icon11.48%   -0.905
 
loading
Vir Biotechnology Inc stock is traded at $7.105, with a volume of 1.55M. It is down -11.48% in the last 24 hours and down -7.07% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$8.01
Open:
$8.01
24h Volume:
1.55M
Relative Volume:
1.70
Market Cap:
$1.06B
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.5824
EPS:
-4.49
Net Cash Flow:
$-473.07M
1W Performance:
-28.16%
1M Performance:
-7.07%
6M Performance:
-27.12%
1Y Performance:
-26.82%
1-Day Range:
Value
$7.00
$8.02
1-Week Range:
Value
$7.00
$9.75
52-Week Range:
Value
$7.00
$13.09

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
Name
Vir Biotechnology Inc
Name
Phone
415-906-4324
Name
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Name
Employee
587
Name
Twitter
@Vir_Biotech
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
VIR's Discussions on Twitter

Compare VIR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
VIR 7.10 1.06B 62.04M -533.34M -473.07M -4.49
VRTX 467.20 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.34 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 565.93 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.51 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.13 24.08B 3.30B -501.07M 1.03B 11.54

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-29-24 Downgrade JP Morgan Overweight → Neutral
Sep-08-23 Downgrade BofA Securities Buy → Neutral
Mar-06-23 Upgrade JP Morgan Neutral → Overweight
Feb-21-23 Upgrade Goldman Neutral → Buy
Jan-27-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-14-22 Initiated SVB Leerink Outperform
Sep-09-22 Initiated Morgan Stanley Underweight
Mar-03-22 Upgrade Robert W. Baird Underperform → Neutral
Dec-21-21 Downgrade Robert W. Baird Neutral → Underperform
Oct-25-21 Upgrade JP Morgan Underweight → Neutral
Sep-22-21 Downgrade Goldman Buy → Neutral
Jun-04-21 Resumed Robert W. Baird Neutral
Jan-27-21 Downgrade JP Morgan Neutral → Underweight
Jan-20-21 Reiterated H.C. Wainwright Buy
Oct-05-20 Initiated BofA Securities Buy
Sep-14-20 Upgrade Goldman Neutral → Buy
Sep-11-20 Upgrade JP Morgan Underweight → Neutral
Aug-20-20 Initiated Needham Buy
Mar-19-20 Downgrade JP Morgan Neutral → Underweight
Mar-13-20 Downgrade Goldman Buy → Neutral
Feb-27-20 Downgrade Robert W. Baird Neutral → Underperform
Feb-04-20 Downgrade JP Morgan Overweight → Neutral
Nov-14-19 Initiated Robert W. Baird Neutral
Nov-05-19 Initiated Barclays Overweight
Nov-05-19 Initiated Cowen Outperform
Nov-05-19 Initiated Goldman Buy
Nov-05-19 Initiated JP Morgan Overweight
View All

Vir Biotechnology Inc Stock (VIR) Latest News

pulisher
07:06 AM

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com

07:06 AM
pulisher
Nov 16, 2024

Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

(VIR) Proactive Strategies - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com

Nov 15, 2024
pulisher
Nov 15, 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire

Nov 15, 2024
pulisher
Nov 13, 2024

Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Nov 13, 2024
pulisher
Nov 08, 2024

Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India

Nov 08, 2024
pulisher
Nov 07, 2024

Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 06, 2024

Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria

Nov 05, 2024
pulisher
Nov 05, 2024

Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Trading (VIR) With Integrated Risk Controls - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 04, 2024

HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $26.00 by Analysts at Barclays - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St

Nov 04, 2024
pulisher
Nov 04, 2024

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance

Nov 04, 2024
pulisher
Nov 02, 2024

Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 02, 2024
pulisher
Nov 02, 2024

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Misses Estimates By $0.51 EPS - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Q3 2024 Earnings Preview - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Stock Traders Buy High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down on Disappointing Earnings - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Reports Q3 2024 Financial Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - BioSpace

Oct 31, 2024
pulisher
Oct 31, 2024

Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c - StreetInsider.com

Oct 31, 2024
pulisher
Oct 25, 2024

Trend Tracker for (VIR) - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 24, 2024

Vir Biotechnology (VIR) to Release Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 18, 2024

State Street Corp's Strategic Acquisition in Vir Biotechnology Inc - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

State Street Corp's Strategic Acquisition in Vir Biotechnology I - GuruFocus.com

Oct 18, 2024
pulisher
Oct 17, 2024

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 - BioSpace

Oct 17, 2024
pulisher
Oct 16, 2024

Was there any good news for Vir Biotechnology Inc (VIR) stock in the last session? - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

Possible Bearish Signals With Vir Biotechnology Insiders Disposing Stock - Simply Wall St

Oct 16, 2024
pulisher
Oct 15, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024 - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

Vir Biotechnology to present hepatitis trial findings - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Vir Biotechnology to present hepatitis trial findings By Investing.com - Investing.com South Africa

Oct 15, 2024
pulisher
Oct 15, 2024

A History of Outperforming Analyst Forecasts and Beating the Odds: Vir Biotechnology Inc (VIR) - SETE News

Oct 15, 2024
pulisher
Oct 14, 2024

Where are the Opportunities in (VIR) - Stock Traders Daily

Oct 14, 2024

Vir Biotechnology Inc Stock (VIR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.04
price down icon 0.87%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):